ROCHESTER, N.Y., May 24, 2006 (PRIMEZONE) -- TGC Ventures International (Pink Sheets:TGVI) announced that it has contracted CMI Inc. to manufacture and make available a homeopathic product that offers relief for sufferers of psoriasis and other skin conditions.
Psoriasis Complex 7003 offers proven efficacy for skin conditions such as acne, rosaceous and psoriasis.
In studies Complex 7003 has proven to be up to 50% more effective in comparison to pharmaceutical and cosmetic products in reducing inflammation. In a Vivo Test carried out on two panels of 50 volunteers, Complex 7003 again improved the clinical signs of skin sensitivity by more than 60% over a 28-day period versus a placebo.
CMI Inc. has developed some of the most innovative cosmeceutical and nutraceutical formulations on the worldwide market today.
About TGC Ventures International Inc.
TGC Ventures International Inc. is a medically related holding company that is targeting the burgeoning multi-trillion dollar Health Care Services and Medical Devices and Supplies Industry. Value proposition resides in both its knowledge infrastructure and in the host of benefits associated with being a United States publicly listed corporation.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.